Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Läärä E, Hinkula M. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study. BJOG 2018;125:1001–1008.
The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes : a cohort and nested case–control study
|Author:||Urpilainen, Elina1; Marttila, Mikko2; Hautakoski, Ari3;|
1Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Centre Oulu, University of Oulu and University Hospital of Oulu
2Children, Adolescents and Families Unit, Department of Welfare, National Institute for Health and Welfare
3Research Unit of Mathematical Sciences, University of Oulu
4Service System Research Unit, National Institute for Health and Welfare
5Centre for Research Methods, Department of Social Research, University of Helsinki
6Institute of Clinical Medicine, University of Eastern Finland
7The Diabetes Centre, Finnish Diabetes Association
8Department of Pathology, Medical Research Centre Oulu, University of Oulu and University Hospital of Oulu, Oulu
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2018092736863
John Wiley & Sons, Inc.,
|Publish Date:|| 2019-02-07
Objective: To obtain evidence of the effects of metformin and statins on the incidence of ovarian cancer in women with type 2 diabetes (T2D).
Design: A retrospective cohort study and nested case–control study.
Setting: The data were obtained from a diabetes database (FinDM) combining information from several nationwide registers.
Population: A cohort of 137 643 women over 40 years old and diagnosed with T2D during 1996–2011 in Finland.
Methods: In full cohort analysis Poisson regression was used to estimate the hazard ratios (HR) in relation to ever use of metformin, insulin other oral anti‐diabetic medication or statins. In the nested case–control analysis 20 controls were matched to each case of ovarian cancer. Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications. The estimates were adjusted for age and duration of T2D.
Main outcome measure: Incidence of ovarian cancer.
Results: In all, 303 women were diagnosed with ovarian cancer during the follow up. Compared with other forms of oral anti‐diabetic medication, metformin (HR 1.02, 95% CI: 0.72–1.45) was not found to be associated with the incidence of ovarian cancer. Neither was there evidence for statins to affect the incidence (HR 0.99, 95% CI: 0.78–1.25). In nested case–control analysis the results were essentially similar.
Conclusions: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in women with T2D was found.
Tweetable abstract: No evidence found for metformin or statins reducing the incidence of ovarian cancer.
BJOG : an international journal of obstetrics and gynaecology
|Pages:||1001 - 1008|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3123 Gynaecology and paediatrics
112 Statistics and probability
This work was supported by grant from Jane and Aatos Erkko Foundation, the Cancer Foundation Grant of Finland and Finnish Government Research Funds admitted for University Hospital of Oulu.
© 2018 Royal College of Obstetricians and Gynaecologists, This is the peer reviewed version of the following article: Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Läärä E, Hinkula M. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study. BJOG 2018;125:1001–1008, which has been published in final form at https://doi.org/10.1111/1471-0528.15151. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.